1,721,054 research outputs found
Going Beyond Counting First Authors in Author Co-citation Analysis
The present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
We provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
We conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
Outcome of chronic HIV-1 patients who interrupt their highly active antiretroviral treatments
Introduction: Highly active antiretroviral treatments (HAART) have become a sin qua non in the live of HIV/AIDS patients most especially for those that have access to it in the developed world.
It has become an unfulfilled dream for those in developing world due to their cost that may not be afforded by the concern patients. Some chronic HIV-1 patients at Institute of Tropical Medicine, Antwerp, Belgium are having their treatments interrupted for reasons other than treatment failure.
Objective of the study: The objectives of the study were to examine the outcome of the patients with chronic HIV-1 infection who interrupt their highly active antiretroviral treatments for reasons other than treatment failure, in terms of rebound of plasma viral loads and decrease in CD4 cell counts and come up with risk factors that are predictive of „good control‟ of the infection.
Methodology: Apart from using exploratoy data analysis with inclusion of nonparametric Kapla-Meier survivorship estimates to compare the risk groups, two major ways of dealing with survival data are used in achieving the desired objectives which are Cox proportional hazards regression model for right censored-data and Weibull parametric regression model for interval censored-data based on the fact that the viral load and CD4 counts are not constantly monitored but are only
measured every 3 to 6 months, the exact time of treatment failure is unknown.
Results: Of the 1296 patients in the follow-up study, 148 had such treatments interruption since 2000. We found that the median failure time for the patients is 2 and 3 months respective for viral and immunological failures. The following variables are identified as risk factors predicting viral and immunological failures; viral load at start HAART on log scale, duration of the disease on log
scale, duration of treatment interruption, CD4 at start HAART, percentage change in CD4 cell
counts and continent of origin. For some of these variables, they reduce the hazard of having viral and CD4 failure with about 8% while some increase the hazards of failure by more than 100%.
Conclusion: The findings from this study show that treatments interruption of at least three months worsen disease outcome. The results suggest that interruptions might be risky, particularly when there is viral rebound of more than 1000 copies/μl and CD4 cell counts less than 20%
koamabayili/VECTRON-author-checklist: VECTRON author checklist
We have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Outcome of chronic HIV-1 patients who interrupt their highly active antiretroviral treatments
Introduction: Highly active antiretroviral treatments (HAART) have become a sin qua non in the live of HIV/AIDS patients most especially for those that have access to it in the developed world.
It has become an unfulfilled dream for those in developing world due to their cost that may not be afforded by the concern patients. Some chronic HIV-1 patients at Institute of Tropical Medicine, Antwerp, Belgium are having their treatments interrupted for reasons other than treatment failure.
Objective of the study: The objectives of the study were to examine the outcome of the patients with chronic HIV-1 infection who interrupt their highly active antiretroviral treatments for reasons other than treatment failure, in terms of rebound of plasma viral loads and decrease in CD4 cell counts and come up with risk factors that are predictive of „good control‟ of the infection.
Methodology: Apart from using exploratoy data analysis with inclusion of nonparametric Kapla-Meier survivorship estimates to compare the risk groups, two major ways of dealing with survival data are used in achieving the desired objectives which are Cox proportional hazards regression model for right censored-data and Weibull parametric regression model for interval censored-data based on the fact that the viral load and CD4 counts are not constantly monitored but are only
measured every 3 to 6 months, the exact time of treatment failure is unknown.
Results: Of the 1296 patients in the follow-up study, 148 had such treatments interruption since 2000. We found that the median failure time for the patients is 2 and 3 months respective for viral and immunological failures. The following variables are identified as risk factors predicting viral and immunological failures; viral load at start HAART on log scale, duration of the disease on log
scale, duration of treatment interruption, CD4 at start HAART, percentage change in CD4 cell
counts and continent of origin. For some of these variables, they reduce the hazard of having viral and CD4 failure with about 8% while some increase the hazards of failure by more than 100%.
Conclusion: The findings from this study show that treatments interruption of at least three months worsen disease outcome. The results suggest that interruptions might be risky, particularly when there is viral rebound of more than 1000 copies/μl and CD4 cell counts less than 20%
Author-wise bibliometric analysis based on entropy.
Author-wise bibliometric analysis based on entropy.</p
- …
